Neovir injectable solution 0.25% 1 2ml amp pc

Description

Composition
Active substance:
1 ml contains: Sodium oksodigidroakridinilatsetat (Neovir ®) – 125 mg.
Excipients:
Sodium citrate – 2.5 mg; citric acid monohydrate – 0.5-1.5 mg (up to pH 7,5-8,3); Water for injection – up to 1 ml.
Description:
Transparent liquid greenish-yellow color.
Product form:
A solution for intramuscular injection of 250 mg / 2 ml in ampoules lighting glass 2 ml; 3, 5 ampoules in blisters of PVC film; 1 contour cellular packaging with instructions for medical use in a stack of cardboard.
Contraindications
Individual intolerance to the drug. Pronounced impairment of renal function (creatinine clearance less than 30 mL / min). Autoimmune diseases. Pregnancy and lactation, children under 18 years.
Used with caution in patients of advanced age.
Dosage
125 mg / ml
Indications
In a monotherapy or in combination therapy: – influenza and other acute respiratory viral diseases, including the background of immunodeficiency states; – infections caused by the virus Herpes simplex, Varicella zoster, Herpes simplex genitalis, including in individuals with compromised immune systems; – cytomegalovirus infection in immunosuppressed persons; – radiation immunodeficiency; – HIV infection; – encephalitis and encephalomyelitis of viral etiology; – acute and chronic hepatitis B and C; – urethritis, epididymitis, prostatitis, cervicitis, and salpingitis chlamydial etiology; – LGV; – cancer; – multiple sclerosis; – candidiasis of the skin and mucous membranes; – HPV infection. Prevention of influenza and other acute respiratory viral infections.
Interaction with other drugs
Physico-chemical incompatibilities and other unwanted interactions have been identified.
Overdose
Neovira® cases of overdose is not described.
pharmachologic effect
Pharmacological group:
Immunostimulatory agent.
Pharmacodynamics:
The preparation possesses antiviral activity against DNA and RNA-virus genome. Chlamydia has a pronounced effect. Neovir ® causes a rapid increase in titers endogenic interferons, especially alpha interferon. Introduction 250 mg Neovir ® intramuscularly detectable serum interferon concentrations equivalent to introduction of 6-9 million IU of recombinant interferon alpha. Peak interferon activity in the blood observed after 1.5-2 hours and is maintained for 16-20 hours after administration Neovir ®. As a result, the body is induced by a cascade of immune responses aiming at the destruction and elimination of pathogens and cells infected by them. Cells – interferon producers acquire the ability to enhanced generation of interferon in response to the re-induction, caused by a pathological agent. This property is preserved for a long time after discontinuation of the drug. Immunomodulatory effects due to the ability to activate Neovir ® hematopoietic stem cells, to normalize the balance of subpopulations of T-lymphocytes, stimulate effector components of the immune system. Neovir ® has a pronounced stimulating effect on the functional activity of macrophages and polymorphonuclear leucocytes, increasing their migration and phagocytic activity. Neovir ® corrects tissue growth: Activates NK-cells, amplifies all forms of cytotoxicity, a positive effect on recovery of adherent cells inhibits their proliferative and metastatic activity.
Pharmacokinetics:
In intramuscular Neovir ® bioavailability is greater than 90%. After administration of 100-500 mg Neovira® maximum plasma concentration is reached in 15-30 min, and 8.3 ug / ml. After 5 hours the only minor amounts Neovir ®, after 6 hours Neovir ® in plasma not detectable. Neovir ® excreted unchanged by the kidneys without being metabolized, with half-life of 1 hr. After 15-30 min after administration Neovira® plasma begin to grow titers endogenic interferons, especially alpha interferon early. Peak 2 revealed the contents of interferon alpha in the plasma of 70 IU / ml after 1.5-2 hours and 110 IU / ml at 8-10 hours after which the interferon alpha content begins to decrease. After 24 hours the concentration of endogenous interferons remains high enough returned to baseline values ​​after 46-48 hours after administration.
Pregnancy and breast-feeding
Safety of Neovir ® in pregnancy and lactation has not been studied, and the drug is contraindicated for use during pregnancy and lactation.
Conditions of supply of pharmacies
On prescription.
side effects
In rare cases, the allergic reaction may cause a rash on the skin. There are low-grade fever, local pain rapidly passing into the injection site. When poor tolerability or soreness at the injection site recommended Neovir ® administered in conjunction with local anesthetic solution (2 ml of 0.25 – 0.5% procaine solution).
special instructions
Information about the possibility of a negative effect of the drug on the performance of potentially hazardous activities that require attention and fast reactions (driving and other vehicles, work with moving machinery, the work manager and operator, etc.) is missing.
Storage conditions
In a dry, dark place at a temperature of from 15 to 25 ° C. Keep out of the reach of children. Clouding Neovir ® solution to a milky white color indicates a violation of storage conditions and unsuitable for use.
Dosing and Administration
Injection is administered intramuscularly, a single therapeutic dose of 250 mg (1 ampoule) or 4-6 mg per kg patient body weight. If necessary Neovir® single dose of the drug can be increased to 500 mg. The course of treatment, unless otherwise stated, consists of a 5 – 7 Neovira® intramuscular injections at a dose of 250 mg every 48 hours, course dose depends on the clinical picture. The duration of the course of 8-12 days. A single prophylactic dose is 250 mg (1 ampoule) or 4-6 mg per kg body weight. With prolonged use of the recommended interval between administrations Neovira® 3 – 7 days. When HIV Neovir ® solution for injection is used in combination with specific antiviral drugs. The treatment course consists of 10 injections of 250 mg every 48 hours between injections. After the course of making a break for 2 months. Perhaps the use of repeated courses of indications.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist